Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
“I am looking forward to working closely with ASSS.”
-PR, 12/13/22
12/13/22
AB/M/22
“A Bum”/V <-V working closely with a bum or ASSS:
“Everyone please sit on your bum and we'll read a story. In the United States, bum is not often used in this sense (though this may vary from dialect to dialect) except in conscious imitation of British English. The term butt is the most common term in North America except in professional contexts such as medical, legal, and scientific where buttocks is generally used or gluteus maximus, gluteus medius, etc. for the muscles specifically.”
https://en.m.wiktionary.org/wiki/bum
A V for …… works very closely with the ASSS in the female human anatomy, just as it does in the decoded date above, 12/13/22.
5 years ago 12/14/17, SP .18, today’s 200 SMA .0009
6/14/22: .0006 —-> .0012
9/14/22: .0006 —-> .0012
12/14/22: ?
Must happen in Q4:
“Versus will be using its patented technologies in-venue, at NFL, NHL, NBA, NCAA, and other sporting events and, beginning in Q4 of this year, in Over-The-Top (OTT) television and streaming media.”
From VS PR, 7/26/22
17 days left in Q4
They are just joking around with these PRs at this juncture, they are far away from US jurisdiction and having a laugh at shareholders expense, literally:
“The deep technical design and installation experience within the ASSS ranks also provides a strong platform for ILUS to roll out its fixed water mist suppression systems in the region”
Another gap to fill at 2.57 as an end of day share price
“147,000 Shares of Common Stock and Accompanying Common Warrants to Purchase up
to 1,889,764 Shares of Common Stock
Pre-Funded Warrants to Purchase Up to 1,742,764 Shares of Common Stock
Shares of Common Stock underlying the Prefunded Warrants and Common Warrants
Placement Agent Warrants to Purchase Up to 94,488 Shares of Common Stock
CNS Pharmaceuticals, Inc.
We are offering 147,000 shares of common stock, together with warrants to purchase 1,889,764 shares of common stock, which we refer to as “common warrants,” at a combined public offering price of $3.175 per share and common warrant (and the shares issuable from time to time upon exercise of the common warrants) pursuant to this prospectus. The shares of common stock and common warrants will be separately issued, but the shares of common stock and common warrants will be issued to purchasers in the ratio of one-to-one. Each common warrant will have an exercise price of $3.03 per share, will be exercisable upon issuance and will expire five years from the date of issuance. This is a “best efforts” offering and we may sell fewer than all of the shares of common stock, warrants and pre-funded warrants offered hereby, which may significantly reduce the amount of proceeds received by us, and investors in this offering will not receive a refund if we do not sell all of the securities offered hereby.
We are also offering 1,742,764 pre-funded warrants to certain purchasers whose purchase of shares of common stock in this offering would otherwise result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock immediately following the consummation of this offering in lieu of shares of common stock that would otherwise result in such purchaser’s beneficial ownership exceeding 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock. The purchase price of each pre-funded warrant and related common warrant will be equal to the public offering price for the common stock and related common warrant in this offering, minus $0.001. Each pre-funded warrant is exercisable for one share of our common stock and has an exercise price of $0.001 per share. For each pre-funded warrant that we sell, the number of shares of common stock we are offering will be reduced on a one-for-one basis.
There is no established public trading market for the pre-funded warrants or common warrants, and we do not expect a market to develop. We do not intend to apply for listing of the pre-funded warrants or common warrants on any securities exchange or other nationally recognized trading system. Without an active trading market, the liquidity of the pre-funded warrants and common warrants will be limited.
This offering will terminate on December 16, 2022, unless we decide to terminate the offering (which we may do at any time in our discretion) prior to that date. We will have one closing for all the securities purchased in this offering. The combined public offering price per share (or pre-funded warrant) and common warrant will be fixed for the duration of this offering.
We have engaged H.C. Wainwright & Co., LLC (“Wainwright”) and Brookline Capital Markets, a division of Arcadia Securities, LLC (“Brookline”) to act as our exclusive placement agents (the “placement agents”) in connection with this offering. Wainwright is acting as exclusive lead placement agent and Brookline is acting as co-placement agent. The placement agents have agreed to use their reasonable best efforts to arrange for the sale of the securities offered by this prospectus. The placement agents are not purchasing or selling any of the securities we are offering and the placement agents are not required to arrange the purchase or sale of any specific number or dollar amount of securities. We have agreed to pay to the placement agents the placement agent fees set forth in the table below, which assumes that we sell all of the securities offered by this prospectus. There is no arrangement for funds to be received in escrow, trust or similar arrangement. There is no minimum number of shares of common stock or pre-funded warrants or minimum aggregate amount of proceeds that is a condition for this offering to close. We may sell fewer than all of the shares of common stock, warrants and pre-funded warrants offered hereby, which may significantly reduce the amount of proceeds received by us, and investors in this offering will not receive a refund if we do not sell all of the securities offered hereby. Because there is no escrow account and no minimum number of securities or amount of proceeds, investors could be in a position where they have invested in us, but we have not raised sufficient proceeds in this offering to adequately fund the intended uses of the proceeds as described in this prospectus. We will bear all costs associated with the offering. See “Plan of Distribution” on page 18 of this prospectus for more information regarding these arrangements.
Our common stock is listed on The Nasdaq Capital Market, or Nasdaq, under the symbol “CNSP”. The last reported sale price of our common stock on Nasdaq on November 30, 2022 was $3.03 per share. We do not intend to list the common warrants or pre-funded warrants on the NASDAQ Capital Market, any other national securities exchange or any other nationally recognized trading system.
The actual public offering price per share and common warrant and the actual public offering price per pre-funded warrant and common warrant will be determined between us, the placement agents and the investors based on market conditions at the time of pricing, and may be at a discount to the current market price of our common stock.
You should read this prospectus, together with additional information described under the headings “Information Incorporated by Reference” and “Where You Can Find More Information,” carefully before you invest in any of our securities.
We are an “emerging growth company” as defined in Section 2(a) of the Securities Act of 1933, as amended, and we have elected to comply with certain reduced public company reporting requirements.
Investing in our securities involves a high degree of risk. See the section entitled “Risk Factors” beginning on page 6 of this prospectus and in the documents incorporated by reference into this prospectus for a discussion of risks that should be considered in connection with an investment in our securities.
Neither the Securities and Exchange Commission nor any other regulatory body has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense.
Per Share and
accompanying
Common Warrant
Per Pre-Funded
Warrant and
accompanying
Common Warrant
Total(2)
Public offering price $ 3.175 $ 3.174 $
5,998,257.94
Placement agent fees (1) $ 0.222 $ 0.222 $
420,000.05
Proceeds to us, before expenses $ 2.953 $ 2.952 $
5,578,257.89
(1) Includes a cash fee of 7.0% of the gross proceeds of this offering. We have also agreed to pay Wainwright a reimbursement for non-accountable expenses equal to $50,000, a reimbursement for legal fees and expenses of Wainwright in the amount of $100,000 and for its clearing expenses in the amount of $15,950. In addition, we have agreed to issue Wainwright, or its designees, warrants to purchase a number of shares of common stock equal to 5.0% of the aggregate number of shares of common stock, including shares of common stock underlying the pre-funded warrants, sold in this offering with an exercise price of $3.969 per share, or 125% of the public offering price per share. See “Plan of Distribution” for additional information about the compensation payable to the placement agents.
(2) Reflects the issuance of 147,000 shares of common stock and pre-funded warrants to purchase 1,742,764 shares of common stock. Because there is no minimum offering amount required as a condition to closing in this offering, the actual public offering amount, placement fees and proceeds to us, if any, are not presently determinable and may be substantially less than the total maximum offering amounts set forth above.
The delivery of the securities offered hereby is expected to be made on or about the termination date of the offering, which will be December 16, 2022, subject to satisfaction of certain customary closing conditions.
Neither the Securities and Exchange Commission nor any other regulatory body has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense.”
12/5/22
https://www.otcmarkets.com/filing/html?id=16242383&guid=x9P-k6tgVvUTOth
Beginning the churn, beautiful to see, will be a fun ride here imo
2.75 gap fill today hopefully, been a long wait as they prepare for being a solution to power grids not being able to currently handle EV charging, the US government toured their facility recently, it’s on the radar as a massive opportunity for State contracts.
50% discount in one day is a big flush out, float is still low even with the effect filing, cure the opioid epidemic, make millions, that simple, hoping for that
OTT TV By Year End as per previous PR, big flush out, .05 a share on pre-split basis, now it could run up with the big news.
Hammer-Millionaires Club
Possible Major Paper and Possible Major Signal:
Hammer-Pe (Pay) …
Here’s where the money for science and satellite’s went:
“Sam Bankman-Fried, the disgraced former CEO of FTX
— the bankrupt cryptocurrency exchange that was worth $32 billion a few weeks ago — has a real knack for self-promotional PR. For years, he cast himself in the likeness of a young boy genius turned business titan, capable of miraculously growing his crypto empire as other players got wiped out. Everyone from Silicon Valley’s top venture capitalists to A-list celebrities bought the act.
But during Bankman-Fried’s press junket of the last few weeks, the onetime wunderkind has spun a new narrative – one in which he was simply an inexperienced and novice businessman who was out of his depth, didn’t know what he was doing, and crucially, didn’t know what was happening at the businesses he founded.”
https://www.cnbc.com/2022/12/05/sam-bankman-fried-could-face-years-in-prison-over-ftx-meltdown.html
Oh by the way, China is quickly equipping its satellite’s with nuclear weapons, so while everyone marvels at SBF just remember that there are real consequences to freedom that malinvestment can cause in the future billionaire playground they seem to enjoy until it is turned to dust because they talk the talk and that’s all they do.
SBF buys off Democrat politicians who then encourage war with Russia, sent billions to Ukraine, that money ended up funneled to FTX which then funded the Democrats in the 2022 election, that’s the circle of corruption, but there’s more, the CEO of FTX is the daughter of the SEC former top employee ! Where’s the FBI? Oh they are pointing their guns at children whiles raiding homes of January 6th supporters and sniffing Melania’s panties in Mar a Lago. I’ll say again, China is equipping its satellites with nuclear weapons, where will the corrupt clowns be when they decide one day to turn the west they infiltrated to dust, invade and take our oil that Biden won’t drill for because he and his son are compromised by multiple nations? Wake up.
95 consecutive trading sessions without closing above the upper bollinger band on the 6 month chart
22 million in Quarterly revenue, seems like about 85 million in annual revenue, 1.2 million float, incredibly undervalued:
“Share Structure
Market Cap Market Cap
3,862,257
12/02/2022
Authorized Shares
Unlimited
11/25/2022
Outstanding Shares
1,501,947
11/25/2022
Restricted
309,547
11/25/2022
Unrestricted
1,192,400
11/25/2022
Held at DTC
64,531
11/25/2022
Float
1,200,000
10/26/2022
Par Value
2.00“
“11:21a ET 12/5/2022 - Globe Newswire
Irwin Naturals Files Q3 2022 Financials
GlobeNewswireDecember 05, 2022
Successful Execution on Ketamine Clinic
Rollup Strategy and Cannabis Licensing to Accelerate Future Growth
LOS ANGELES, Dec. 05, 2022 (GLOBE NEWSWIRE) -- Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) ("Irwin" or the "Company") announced the Company filed results for its third quarter of fiscal 2022, the period ended September 30, 2022 on www.sedar.com.
Sean Sand, CFO, stated, "Despite cost pressures continuing through the quarter, we were able to grow our Gross Margins by +4.8% over Q3 2021. The Gross Margin increase can be attributed to sales mix coupled with the early success of a targeted price increase across the market. In addition, we were still able to maintain positive Operating Profits despite the additions in the cost base to support the early phases of the Emergence and Licensing businesses."
Mr. Sand continued, "Our balance remains strong, and have access to considerable working capital to fund our accelerated growth plans. To date we have closed or announced agreements to acquire entities or assets amounting to 18 clinics and anticipate several more closing as we exit 2022 and in the coming quarters. In addition, we are continuing our rollout of our licensing deals, which now sees us in six states and in Canada."
Financial Summary
Three months ended Nine Months Ended
(in thousands) September 30, $ % September 30, $ %
Combined Statement of Profit 2022 2021 Change Change 2022
2021
Change Change
Non-CBD operating revenue $ 20,346 $ 20,899 $ (553 ) -2.6 % $ 61,205 $ 66,334 $ (5,129 ) -7.7 %
CBD operating revenue 1,679 2,774 (1,095 ) -39.5 % 5,221 8,067 (2,846 ) -35.3 %
Total Operating Revenue 22,024 23,673 (1,649 ) -7.0 % 66,427 74,401 (7,974 ) -10.7 %
Gross Profit 10,603 10,117 486 4.8 % 31,208 33,970 (2,762 ) -8.1 %
Income from Operations 622 1,232 (610 ) -49.5 % 3,653 8,170 (4,517 ) -55.3 %
Net Profit / (Loss) (583 ) (1,466 ) 883 60.2 % 1,109 5,226 (4,117 ) -78.8 %
As of As of $ %
Statement of Financial Position Sept 30, 2022 Dec 31, 2021 Change Change
Total assets 71,527 47,219 24,308 51.5 %
Total liabilities 41,027 24,103 16,924 70.2 %
Klee Irwin, CEO, commented, "In Q3, Irwin Naturals moved close to becoming the world's largest chain of dedicated psychedelic mental health clinics. In addition, we are rapidly on our way to doubling our profits from last year on an annualized basis based on potential acquisitions in the psychedelic mental. The mental healthcare industry is a 1.5 trillion dollar behemoth in desperate need of a disruptive sea change. With standard treatments having an average effectiveness of approximately 17%, the drastic improvements of results from psychedelic treatments is that sea change. We currently have no meaningful competitors in our rearview mirror and intend to be the world's first chain of clinics in this sector to exceed 100 locations."
Financial Highlights
The 7% decline in overall operating revenues were due largely to supply issues in the CBD segment, related to a reduction in supply at a key supplier. The decline, though still down from prior year, is recovering quarter over quarter. Production of CBD products has restarted at the Company's manufacturer. Other factors impacting sales related to order timing and the loss of distribution of certain non-CBD mass market products.
Income from operations in Q3 2022 came in at $0.6 million, as compared to $1.2M million for the same period in the prior year. The reduction in income was driven primarily by the aforementioned decrease in business volume and startup costs related to Emergence by Irwin Naturals (ketamine clinics) and Irwin Naturals Cannabis (intellectual property licensing to the cannabis industry).
The overall decrease in business volume paired with startup costs related to the Company's initiatives in cannabis and the aforementioned startup costs, resulted in a decrease in Adjusted EBITDA1 to $0.5 million.
Three months ended Nine months ended
(in thousands) September 30, $ % September 30, $ %
2022 2021 Change Change 2022 2021 Change Change
Net Profit $ (583 ) $ (1,466 ) $ 883 60.2 % $ 1,109 $ 5,226 $ (4,117 ) -78.8 %
Interest Expense 181 34 147 432.4 % 541 91 450 494.5 %
Income Tax Expense 1,024 162 862 532.1 % 2,003 351 1,652 470.7 %
Depreciation and Amortization 468 353 115 32.6 % 1,299 1,061 238 22.4 %
EBITDA $ 1,090 $ (917 ) $ 2,007 218.9 % $ 4,952 $ 6,729 $ (1,777 ) -26.4 %
Foreign Exchange (Gain) / Loss (33 ) - (33 ) 100.0 % (45 ) - (45 ) 100.0 %
Listing Expenses - 2,502 (2,502 ) 0.0 % - 2,502 (2,502 ) 0.0 %
Other Income - - - 100.0 % - - - 0.0 %
Adjusted EBITDA $ 1,057 $ 1,585 $ (528 ) -33.3 % $ 4,907 $ 9,231 $ (4,324 ) -46.8 %
1EBITDA is a non IFRS metric that management believes provides a metric for rapid analysis of the underlying strength of the business. A reconciliation from IFRS to EBITDA is provided in the accompanying table above and at the end of this release.
Cash provided by operating activities by Irwin were $3.6 million and $14.6 million for the nine months ended September 30, 2022 and 2021, respectively. The decrease in operating cash flows is primarily due to lower operating revenue and temporary unfavourability to working capital led by the timing of payments to the Company's primary product manufacturer couple with increased cash related to Emergence startup costs.
Operational Highlights & Subsequent Events
Irwin Naturals is executing on an aggressive expansion strategy into the high-growth cannabis and psychedelics sectors. The Company intends to leverage its household name brand status to drive an aggressive rollup of mental health clinics (the Company is focused on ketamine clinics, as this is currently the only FDA-approved and/or regulated psychedelic substance). Furthermore, the Company has begun executing on its brand licensing strategy throughout the US. To date, the Company has announced agreements to acquire entities or assets; or completed the acquisition of such entities or assets amounting to 17 clinics, as well as the signing of seven brand licensing deals that will see Irwin Naturals products enhanced with THC be offered in California, Colorado, New Mexico, Mississippi, Ohio, Michigan and Canada.
State Clinic Acquisitions
Florida Ketamine Health Centers (5 clinics)
Florida Mind Health (3 clinics)
Dura Medical (1 clinic)
Iowa Midwest Ketafusion
New Hampshire New England Ketamine
Mexico Ketamine Health Centers
Vermont Preventive Medicine
Georgia Invictus Clinics (2 clinics)
Washington Tri-Cities Infusion
Idaho Ketamine Infusions of Idaho
Ohio Happier You
Kentucky Serenity Health
State Brand License Recipients
California The Hive Laboratory, LLC
Colorado Larsen Group II, LLC
Ohio BeneLeaves, Ltd
New Mexico Assurance Laboratories, LLC
Canada Entourage Health Corp.
Mississippi Mockingbird Cannabis, LLC
Michigan 42 Degrees Processing, LLC
”
HammerPay Q4, purchase of Wallet Factory, Going Global soon, Hammer Millionaires Club?
“HAMMER ANNOUNCES LETTER OF INTENT TO AQUIRE WALLET FACTORY
October 19, 2022
Sarasota, FL, October 18, 2022 – Hammer Fiber Optics Holdings Corp d/b/a Hammer Technology Holdings(OTCQB: HMMR), announced today that it has entered into a non-binding letter of intent with shareholders of Mobile Finance Group Ltd trading under the brand name of Wallet Factory, a FinTech provider of digital finance services and enterprise-grade e-Wallet platforms. The LOI contemplates that the parties will enter into a definitive agreement pursuant to which HMMR will acquire a controlling interest in the outstanding common stock of Mobile Finance Group Ltd (“Wallet Factory”).
Wallet Factory offers digital wallet software solutions such as all-in-one e-Wallets with B2B and B2C payment platforms and cloud-based customer reward programs to banks, wallet operators, telecoms and large retailers. Founded in 2016, Wallet Factory is presently operating more than 25 revenue-generating projects in 12 countries across 5 continents, boasting over 4.5M end customers worldwide, as well as garnering revenues rising at a steady CAGR of 40% since its inception.
Wallet Factory has taken a leading position in the Wallet-as-a-Service (WaaS) business within the global market place winning the GOLD Stevie® Award for Innovation in Technology Development in the Financial Services category of the third annual Middle East & North Africa Stevie Awards, sponsored by the RAK Chamber of Commerce & Industry (read article here). Wallet Factory CEO Mikhail Miro, a member of the Forbes Business Council, was recently featured in an article by Forbes (read article here) to discuss the benefits of the WaaS model. The company itself has been featured in articles by The Fintech Times, FinExtra and other fintech publications relating to their efforts to drive digital financial inclusion.
Michael Cothill, Executive Chairman of HMMR said, “With the announcement of the HammerPay platform coming to Africa this quarter our focus is now on strategic acquisitions and partnerships that will augment our FinTech initiative and open up new avenues of revenue. Adding Wallet Factory to our portfolio will allow us to rapidly expand into other lucrative unbanked markets such as Central and South America, East Asia and other international markets where Wallet Factory currently offer services. Wallet Factory acquisition will not only bring in revenues day-one, but it also creates a perfect synergy to expand the capabilities and distribution channels of the HammerPay platform.”
Konstantin Vaysman, Executive Chairman and Co-Founder of Wallet Factory said of the proposed deal, “This is the case of two companies having a perfectly aligned vision for the future of digital finance. Both our organizations view WaaS as the primary way for financial institutions and businesses to digitize their value chain through the seamless integration of various financial services embedded either within their existing platforms or as stand-alone offerings. It’s a client-first approach that is going to have a major impact on banking and commerce in developing countries. HMMR and their HammerPay platform are certainly poised to take advantage of these opportunities but when you pair their offering with our suite of mobile point-of-sale, KYC/AML services and loyalty programs together, we can offer a vertically integrated product with a global reach that can fit any need.”
Completion of the acquisition is subject to due diligence and approval of the stock purchase agreement between the parties which has been agreed upon by management but not ratified by the Board of Directors of the companies. As the transaction is finalized, HMMR will publicly disclose required information either through press releases or SEC filings, as appropriate.”
https://hmmrgroup.com/media/f/hammer-announces-letter-of-intent-to-aquire-wallet-factory
Jianzhi
Education
Technology
“He uses “new planes gettin’ broken-in” to illustrate. Guru continues, “It’s literally paper planes, the brand [logo for Roc Nation]. Like, when you’re tryin’ [on] new clothes, you’re breakin’ in your clothes. But that’s Emory—that’s Emory’s thing: paper planes gettin’ broken in.” Moments later, Guru points out that the lyric also references a new private jet purchase that JAY-Z made. Only those in his inner-most circle could catch the reference. “This man just ordered a new plane.” He calls that crew-level. “But then it’s ‘new planes gettin’ broken in,‘” meaning achieving higher altitudes altogether. “New levels of existence.””
https://ambrosiaforheads.com/2022/08/young-guru-hidden-meanings-jay-z-did-verse/
Happy Birthday JZ
“Can't you see? We gettin' money up under you
Can't you see the private jets flyin' over you?
Maybach bumper sticker read, "What would Hova do?"
Jay is chillin'(uh), 'Ye is chillin' (uh)
What more can I say? We killin' 'em
Hold up, before we end this campaign
As you can see, we done bodied the damn lames
Lord, please let them accept the things they can't change
And pray that all of their pain be champagne
Source: Musixmatch
Songwriters: Shawn Carter / James Brown / Kirk Robinson / Kanye Omari West / Harry Woods / Roy C. Hammond / Reginald Connelly / Unknown Composer Author / J Campbell
Otis lyrics © Wb Music Corp., Emi Blackwood Music Inc., Carter Boys Music, Kassner Associated Publishers Ltd., Dynatone Publishing Company, Campbell Connelly And Co. Ltd., First Priority Music, Campbell Connelly And Co.ltd., Intersong-usa Inc., Swing Beat Songs, Intersong-usa, Inc., Please Gimme My Publishing Inc, Hot Butter Milk Music Inc, Hot Butter Milk Music, Inc., Campbell Connelly & Co Ltd”
Haven’t posted in 10 days = volume
The China infiltrated US financial system look around your offices for the nearest spies amongst you, you can damn well be sure the bought and paid for understaffed SEC and financial authorities don’t care, too busy doing taxpayer funded Coke and Meth after hours.
And all the market makers on this stock can kiss my a$$ as well, the China infiltrated US financial system look around your offices for the nearest spies amongst you, you can damn well be sure the bought and paid for understaffed SEC and financial authorities don’t care, too busy doing Coke and Meth after hours.
Updated Deals (in order of occurrence) since June close of 1.44 :
NASA,
Dhruva,
Teledyne,
Exo-Space,
SpaceX,
Momentus,
Parsons,
an announcement of revenue greater than Q2,
Exo-Space again,
Vaya Space,
Mission Space,
Dawn Aerospace,
GTM Advanced Structures,
Capital C,
NOAA Tier 1 license,
AS9100 Rev D Certification,
current share price 1.70
4 industry awards issued to company/employees in the above time-frame.
Since the last close above the upper bollinger band on 7/21 it has closed below the lower bollinger band 8 times without a return to the upper bollinger band.
Yet investors had millions to lose in the FTX crypto Ponzi scheme
Science is the priority in the U.S. administration, academic and financial leadership or is it taking pictures with SBF and partying? I think we all see the truth. Actions speak louder than empty claims of dedication to science. The one thing this Shareprice has done that is positive is prove they entire US government, financial and tech leadership to be complete double-talking frauds until proven otherwise. Go put some more money in FTX and then go on TV and claim you care about science you complete frauds.
December update due:
“Nov 2
$MDMP sold 2 loads oil from Brown lease, and a load from Oglesby and Lindley. All in October. #MDMP
mdmpermian
@mdmpermian
·
Oct 6
$MDMP has sold its third load of oil from Brown #1 well. More to come! #MDMP
mdmpermian
@mdmpermian
·
Sep 23
$MDMP sold second load of oil this month on Brown #1. Load called in for Lindley and Oglesby. Peacock continues strong natural gas sales. #MDMP
mdmpermian
@mdmpermian
·
Sep 8
Field Update: $MDMP has started shipping oil from the Brown #1. Transoil has picked up the first load, 2 more scheduled to go this month. #MDMP
mdmpermian
@mdmpermian
·
Sep 2
$MDMP August Field Updates posted to
@OTCMarkets”
“9:14a ET 9/30/2022 - Dow Jones
Coffee Holding to Merge with Bulk Logistics Provider
By Dean Seal
Coffee Holding Co. has signed an agreement with the privately held logistics firm Delta Corp Holdings Ltd. to merge into a single entity that will operate under the name Pubco.
The wholesale coffee roaster and dealer said Friday that under the terms of the deal, its shareholders will receive one share of the new company for each Coffee Holding share they own, while Delta stockholders will exchange their shares for $625 million in ordinary shares of the new company, at an implied share price of $5.50.
Pubco will have an implied enterprise value of about $655 million, with Delta shareholders collectively owning about 95% of the outstanding shares and Coffee Holdings shareholders owning the rest.
Trading in shares of Coffee Holdings, which closed at $2.42 on Thursday, was halted when the news was released. After premarket trading resumed at 9 a.m. ET, shares shot up as high as 30%, sank to a loss minutes later and continued to fluctuate before market open. They are down more than 44% this year.
The transaction is expected to close in early 2023, pending approval from Coffee Holding shareholders, and that Pubco is slated to trade under the ticker symbol DLOG on the Nasdaq.
Pubco will be engaged in Bulk & Energy logistics, fuel supply, asset management-related services and commodities, including coffee, with a multinational footprint.
The combined company will be led by Delta's existing management team, while Coffee Holding will operate as a subsidiary of Delta and be led by its current president and chief executive, Andrew Gordon, who called the transaction a "transformative next step" for the company.
Delta Chief Executive Mudit Paliwal said the merger will allow the company to expand its business and enter new markets, while broadening its "energy transition, sustainability and environmental stewardship related service offerings."
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
September 30, 2022 09:14 ET (13:14 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.”
DRNG = Derange
What was a deranged event in history?
Sandy Hook, 12/14/22 is 10 year anniversary
Last two price bottoms were:
6/14/22: .0006 —-> .0012
9/14/22: .0006 —-> .0012
12/14/22: ?
666?
SMA in great shape if some business wants to buy this shell.
Too much debt too many shares :
“As of September 30, 2022, current assets were $355 million, including cash and cash equivalents of $130 million. The Company had working capital of $85 million and senior secured term loan debt, net of discount and issuance costs, of $380 million.Total shares on a fully converted basis were 437,484,245 as of September 30, 2022.”
At this moment there are many Nasdaq stocks w/ over 100 million OS, annual revenues of between 5 and 10 million and huge quarterly losses upwards of 10 million, trading in dollars, this quarterly report puts RJDG at over .10 cents minimum when placed in direct financial comparison, and in my view is actually a better company in terms of financials than the few Nasdaq stocks I just reviewed wondering how they could be trading in dollars with those numbers. Investors will be looking for up and coming companies with good asset/liability ratios in this timeframe as they cycle out of overvalued tech stocks, imo.
“Jourdan Resources Inc. Management’s Discussion and Analysis
For the nine months ended September 30, 2022 and 2021
On April 17, 2017, the Company entered into an option agreement with Infinite Ore Corp. (previously Alix Resources Corp,) (“Infinite”) whereby Infinite granted the Company an option to acquire several lithium mining claims in Quebec. These claims lapsed in 2020, and Infinite made a claim for damages against the Company. On April 16, 2021, the Company and Infinite settled the outstanding amount by the issuance of 4,500,000 shares of Jourdan at a deemed price of $0.06 per share for an aggregate amount of $270,000.
On July 7, 2021, the Company completed a private placement flow-through financing for gross proceeds of $720,000. Pursuant to the offering, the Company issued 14,400,000 units at a price of $0.05 per unit. Each unit was issued on a flow-through basis and consists of one common share of the Company and one-half of one common share purchase warrant. Each whole warrant entitles the holder to acquire one additional common share of the Company at an exercise price of $0.07 until July 7, 2023.
On November 25, 2021, the Company completed a private placement financing for gross proceeds of $455,000. Pursuant to the offering, the Company issued 9,100,000 units at a price of $0.05 per unit. Each unit consists of one common share of the Company and one-half of one common share purchase warrant. Each whole warrant entitles the holder to acquire one additional common share of the Company at an exercise price of $0.07 until November 25, 2023.
On December 31, 2021, the Company completed a private placement flow-through financing for gross proceeds of $1,350,000. Pursuant to the offering, the Company issued 27,000,000 units at a price of $0.05 per unit. Each unit was issued on a flow-through basis and consists of one common share of the Company and one-half of one common share purchase warrant. Each whole warrant entitles the holder to acquire one additional common share of the Company at an exercise price of $0.07 until December 31, 2023.
On July 29, 2022, the Company completed a private placement financing of (i) 9,512,500 units at a price of $0.08 per unit, and (ii) 14,000,000 common shares of the Company issued on a flow-through basis at a price of $0.10 per flow-through share for aggregate gross proceeds of $2,161,000. Each unit consists of one common share of the Company and one common share purchase warrant, which will entitle the holder to acquire one additional common share of the Company at an exercise price of $0.10 per share until July 29, 2024.
In connection with the offering, the Company paid finder’s fees of $81,000 in cash and issued 810,000 non-transferable finder’s warrants to Roche Securities Ltd. in accordance with TSXV policies. Each finder’s warrant entitles the holder thereof to acquire one common share of the Company at a price of $0.10 per share until July 29, 2024.”
Good luck absorbing all those warrants the next few years.
Reverse split soon imo
“Up to 1,349,206 Shares of Common Stock and Accompanying Common Warrants to Purchase up to ?????????????Shares of Common Stock
Pre-Funded Warrants to Purchase Up to 1,349,206 Shares of Common Stock
Shares of Common Stock underlying the Prefunded Warrants and Common Warrants
Placement Agent Warrants to Purchase Up to 67,460 Shares of Common Stock
CNS Pharmaceuticals, Inc.
We are offering 1,349,206 shares of common stock, together with warrants to purchase 1,349,206 shares of common stock, which we refer to as “common warrants,” at an assumed combined public offering price of $6.30 per share and common warrant, which is equal to the last reported sale price per share of our common stock on The Nasdaq Capital Market, on November 25, 2022, adjusted to reflect the 1-for-30 reverse split we will effect at 4:01pm Eastern time on November 28, 2022 (and the shares issuable from time to time upon exercise of the common warrants) pursuant to this prospectus. The shares of common stock and common warrants will be separately issued, but the shares of common stock and common warrants will be issued to purchasers in the ratio of one-to-one. Each common warrant will have an exercise price of $6.30 per share (100% of the combined public offering price), will be exercisable upon issuance and will expire five years from the date of issuance. This is a “best efforts” offering and we may sell fewer than all of the shares of common stock, warrants and pre-funded warrants offered hereby, which may significantly reduce the amount of proceeds received by us, and investors in this offering will not receive a refund if we do not sell all of the securities offered hereby.
We are also offering to certain purchasers whose purchase of shares of common stock in this offering would otherwise result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock immediately following the consummation of this offering, the opportunity to purchase, if any such purchaser so chooses, pre-funded warrants, in lieu of shares of common stock that would otherwise result in such purchaser’s beneficial ownership exceeding 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock. The purchase price of each pre-funded warrant and related common warrant will be equal to the public offering price for the common stock and related common warrant in this offering, minus $0.001. Each pre-funded warrant is exercisable for one share of our common stock and has an exercise price of $0.001 per share. For each pre-funded warrant that we sell, the number of shares of common stock we are offering will be reduced on a one-for-one basis.
There is no established public trading market for the pre-funded warrants or common warrants, and we do not expect a market to develop. We do not intend to apply for listing of the pre-funded warrants or common warrants on any securities exchange or other nationally recognized trading system. Without an active trading market, the liquidity of the pre-funded warrants and common warrants will be limited.
This offering will terminate on December 16, 2022, unless we decide to terminate the offering (which we may do at any time in our discretion) prior to that date. We will have one closing for all the securities purchased in this offering. The combined public offering price per share (or pre-funded warrant) and common warrant will be fixed for the duration of this offering.”
https://www.otcmarkets.com/filing/html?id=16225783&guid=QbG-keoFaVaqJth
This SP post RS is what the CEO meant by “many times its current value”
“9:21a ET 3/9/2022 - Benzinga
CNS Pharmaceuticals Addresses Recent Share Price Activity
Video from John Climaco, CEO of CNS Pharmaceuticals now available on the Company's website
HOUSTON, March 9, 2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today released a video to shareholders reiterating its operational and clinical progress for lead product candidate, Berubicin, and addressing recent share price activity.
"The divergence that exists between our operational strength and share price is top of mind for myself and the whole team at CNS Pharmaceuticals. As a shareholder of CNS Pharma, I share in the frustrations as it pertains to the share price and fluctuation in the market â?? both of which are things out of our control. However, as the CEO, what I do have control over is executing on the day-to-day operations, which I want to reiterate and emphasize, have simply never been stronger. We continue to enroll patients around the world in our potentially pivotal study of Berubicin in the treatment of adult GBM. We have the leading minds in the field around the world working on this trial with us and we have encouraging ongoing dialogue with the FDA to ensure that our potentially pivotal trial continues to represent the state-of-the-art in the field. So, while what we cannot control remains to be a point of frustration, we are committed to continuing to execute our operational excellence to drive recognition in the market of Berubicin and what we believe could be its immense potential for patients â?? the key driver for ultimately generating shareholder value and tremendous hope for GBM patients worldwide," commented John Climaco, CEO of CNS Pharmaceuticals. "We put our heads down every day and continue to charge forward in our mission to change the game in glioblastoma via Berubicin."”
Reverse split soon imo, the equity raise to pay off debt is just exchanging old for new debt, SP isn’t high enough to thieve much more from shareholders
Needs a 10:1 RS too many shares imo
Reverse split soon imo, back to .1901 gap
“7:30a ET 11/30/2022 - Globe Newswire
Irwin Naturals Leverages Household Brand Status in Effort to be World's Largest Chain of Psychedelic Mental Health Clinics
GlobeNewswireNovember 30, 2022
LOS ANGELES, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Irwin Naturals Inc.(CSE: IWIN) (OTC: IWINF) (FRA: 97X) ("Irwin" or the "Company") announced today it reached a binding, arms-length, agreement to acquire Serenity Health, LLC in Louisville, Kentucky, on November 25, 2022. The move continues Irwin's national ketamine clinic rollup strategy that has seen the Company move quickly toward its goal of building Irwin Naturals Emergence into the world's largest chain of psychedelic mental health clinics. Irwin Naturals was founded in 1994, building itself into a nationally renowned company with its first-in-class line of nutraceuticals that are available in more than 100,000 stores across North America. The Irwin Naturals brand is recognized in 80 percent of American households.1
Klee Irwin, CEO of Irwin Naturals, said, "With each clinic we bring under the umbrella of Irwin Naturals Emergence, we take another step toward the forefront of this new approach to mental healthcare. We are the world's first household name to enter the space and are moving fast with the goal of being the first mover in this market."
Irwin Naturals Emergence already includes clinics in Florida, Vermont, New Hampshire, Iowa, and Georgia. Currently, ketamine is the only psychedelic available for use in the United States outside of clinical trials when used as prescribed. However, MDMA and psilocybin may be authorized for therapeutic use in the future. This creates the possibility of radically changing the way we treat mental-health concerns.
Beth Ann Nevius, cofounder and CEO of Serenity Health, said, "What impressed us about Irwin's approach to America's mental health crisis is its philosophy of using national scale to drive down patient costs. Furthermore, the Irwin team has proven itself capable of building a national brand with an exceptionally faithful customer base. We are looking forward to becoming part of the Irwin team and taking this great brand nationwide, making mental healthcare accessible to all."
Irwin Naturals Emergence is a wholly owned subsidiary of Irwin Naturals, and it was formed when the Company decided to enter the fast-growing sector of psychedelic mental healthcare. Over the past year, Irwin Naturals Emergence has identified ketamine clinics that practice a high standard of care to explore the possibility of adding these clinics to the national chain. This offers the possibility of increased economic efficiency because of the national scale of the operation that could help drive down operating costs, making it possible to pass savings along to the consumer in the form of sliding-scale discounts and even pro-bono treatments for those in need. Irwin Naturals' name and reputation makes it an impactful voice in this new area of mental healthcare due to the Company's history in safely caring for the health of its patients vouching for the safety and the efficacy of psychedelic treatment.
Irwin added, "We see ourselves as the Coca Cola first mover, and will be leveraging our brand equity and status as a cult brand to expand rapidly as society embraces the psychedelic mental health revolution. This is important because, as a psychedelic, ketamine is an effective treatment for many mental health disorders. However, some Americans are not clear on its potential. The trusted Irwin brand will be the welcome face of a familiar friend in a crowd of strangers - making this life-saving solution a bit less intimidating to those in need."
The Agreement is subject to certain customary closing conditions and regulatory approvals. The total consideration will be paid in upfront and deferred consideration. Also included are contingent payments based on milestones related to expansion and profitability goals.”
Heading toward 10:1 Reverse Split imo, lower bollinger band on 6 month chart below .85
Reverse split soon, way too many shares at this development stage, company will enjoy a Vegas vacation in the meantime:
“8:31a ET 11/22/2022 - BusinessWire
Cenntro to Exhibit Full Logistar EV Line and All Electric iChassis at CES 2023
--Booth Meetings with Management Available for Institutional Investors, Sell-Side and Industry Analysts
Cenntro Electric Group Limited (NASDAQ: CENN), a leading EV technology company with advanced, market-validated electric commercial vehicles, today announced that it will showcase its vehicles at the upcoming 2023 Consumer Electronics Show (CES(R)), one of world's largest technology trade shows taking place January 5-8, 2023 in Las Vegas. In conjunction with CES, the Company will also hold a press event on January 4th to unveil its production version of the iChassis and hold investor meetings at its booth to provide an overview of Cenntro and discuss the future of Mobility.
"CES is the world's leading event for showcasing the future of sustainable transportation and technology, and we are looking forward to presenting our fleet and iChassis to attendees," said Peter Wang, Chairman and CEO of Cenntro. "Cenntro is dedicated to delivering Electric Vehicle solutions that municipalities and corporate fleets, both large and small, can utilize to reduce emissions without sacrificing performance. Our purpose-built ECVs are designed to support urban logistics and services, last-mile delivery and other commercial applications purpose-built for the demands of the city.
"Technology has become an integral differentiator in EV vehicles and transportation, and CES(R) is the most influential tech tradeshow worldwide to unveil Cenntro's iChassis. The iChassis opens the promise of automated and autonomous driving to new applications and businesses today, moving beyond the roads and bringing autonomy to everyday commercial functions from warehouses to surveillance to mobile vending and delivery. We believe these functions are the sweet spot for adoption of automated and autonomous vehicles and will drive new innovation for the implementation of autonomy," concluded Wang.
Cenntro Exhibit at Booth 5840
Cenntro's exhibit at Booth 5840 in the West Hall will be an almost 10,000 square feet display of its complete All Electric Commercial product line. The exhibit will include the full Logistar line which features the versatile, compact cargo van, the LS100, the multi-purpose LS200 available in van or box truck configurations, the segment defining LS260 van and the Class 4 LS400 purpose-built for last mile delivery and urban services. Cenntro will also showcase its Off-Road Vehicle offerings, the TeeMak, and the Antric One, an auto grade four wheeled e-cargo bike purpose-built for delivery services and general cargo transport.
Press Event for All Electric iChassis
Cenntro's production version, state of the art All Electric iChassis, will make its world premiere at a press conference on Tuesday, January 4, 2023 at 12:00 pm at the Mandalay Bay Hotel, the venue for CES Press Conferences. The open-platform, fully programmable iChassis has been designed for automated and autonomous driving. The iChassis opens innovation to third-parties to develop their own software and design hardware to control and maneuver the vehicle and to develop new applications that are unique to their needs.
Investor Meetings & Mobility Dinner
Cenntro's executive team will hold meetings with institutional investors, sell-side and industry analysts to learn more about the Company and its products at booth 5840 in the West Hall of the Las Vegas Convention Center January 5-8, 2023.”
Does not exist on the internet: Xiamen Shengruihao Technology Co., Ltd, no web presence, website or mention, it’s likely it was invented by blue hat, until they can prove it is tangible and relevant.